Ruxolitinib + Standard Treatment for Brain Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this research is to test the safety and effectiveness of the investigational drug ruxolitinib when it is combined with standard of care treatment (radiation therapy and temozolomide) for the treatment of newly diagnosed glioblastoma. Half the people in the study will be assigned to take the study drug ruxolitinib in addition to the standard of care temozolomide and radiation therapy and the other half will be assigned to the standard of care temozolomide and radiation therapy only. This assignment will be randomized in a 1-to-1 ratio, like the flip of a coin.
Who Is on the Research Team?
Manmeet Ahluwalia, M.D., MBA
Principal Investigator
Miami Cancer Institute at Baptist Health, Inc.
Are You a Good Fit for This Trial?
This trial is for individuals newly diagnosed with glioblastoma, a type of brain cancer. Participants should not have received prior treatments for this condition. Specific eligibility criteria are not provided, but typically include factors like age, overall health status, and the stage of the tumor.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Radiation and Temozolomide
Participants receive radiation therapy and temozolomide, with or without ruxolitinib, during this phase
Maintenance
Participants continue with temozolomide, with or without ruxolitinib, after radiation therapy is complete
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Radiation Therapy
- Ruxolitinib
- Temozolomide
Find a Clinic Near You
Who Is Running the Clinical Trial?
Baptist Health South Florida
Lead Sponsor
Incyte Corporation
Industry Sponsor
Steven Stein
Incyte Corporation
Chief Medical Officer since 2015
MD from University of Witwatersrand
Hervé Hoppenot
Incyte Corporation
Chief Executive Officer since 2014
MBA from ESSEC Business School